Patent · US Active

Lymphocyte biomarkers for determining the clinical response to cell therapy

US10660920B2 · kind B2 · utility

1Cited by

0References

16Claims

0Family size

Assignees

TIGENIX NV · BE
Tigenix, S.A.U. · ES

Inventors

Olga De La Rosa · Tres Cantos, ES
Eleuterio Lombardo · Tres Cantos, ES
Wilfried Dalemans · Leuven, BE

Key dates

Filing date	Mar 17, 2014
Grant date	May 26, 2020
Priority date	—
Expiry date	May 23, 2035

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a method for determining the clinical prognosis of a human subject to the administration of a pharmaceutical composition comprising of stem cells (preferably mesenchymal stem cells), stromal cells, regulatory T-cells, fibroblasts and combinations thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.